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LETTERS TO THE EDITOR
A Spectrum of Novel Mutations in the Protoporphyrinogen
Oxidase Gene in 13 Families with Variegate Porphyria
To the Editor:
Variegate porphyria (VP) (OMIM 176000), one of the acute
hepatic porphyrias, is caused by a partial de®ciency of proto-
porphyrinogen oxidase (PPO) (EC 1.3.3.4), the penultimate
enzyme in the porphyrin-heme biosynthetic pathway. Clinically,
cutaneous and/or neuropsychiatric symptoms can occur in affected
individuals (Bickers et al, 1993; Frank and Christiano, 1997). The
cutaneous ®ndings include photosensitivity, increased cutaneous
fragility, and blistering on the sun-exposed areas of the skin.
Neurologic symptoms can present as acute porphyric attacks,
including abdominal pain, muscle weakness, and respiratory
paralysis that can lead to coma and death (Crimlisk, 1997; Frank
and Christiano, 1997).
VP is usually inherited in an autosomal dominant fashion with
incomplete penetrance. The human PPO cDNA and gene were
recently cloned and mapped to chromosome 1q22±23 (Nishimura
et al, 1995; Taketani et al, 1995), and mutations were identi®ed in
several families with VP (Deybach et al, 1996; Lam et al, 1996a, b;
Meissner et al, 1996; Roberts et al, 1996, 1998; Warnich et al, 1996;
Dailey and Dailey, 1997; deRooij et al, 1997; Frank and Christiano,
1997; Kauppinen et al, 1997; Frank et al, 1997, 1998a±e, 1999a,
2001; Frank and Christiano, 1998; Corrigall et al, 1998; Whatley
et al, 1999).
Here, we studied VP patients of different ethnic origin, ages, and
both genders from 13 unrelated families and 100 unrelated,
unaffected control individuals. All patients and family members,
their familiar relationship, ethnic origin, and mutations are
summarized in Table I.
EDTA containing blood samples were collected from all
individuals with informed consent. DNA isolation, PCR ampli®-
cation, mutation detection/con®rmation, and veri®cation of
paternity was carried out as previously described in detail (Frank
et al, 1999a, b).
We identi®ed 11 different mutations in the PPO gene, including
three nonsense mutations (Q189X, E191X, and Q435X), four
frameshift mutations (1083delT, 1091insA, 915delTG, and
1144delGT), three splice site mutations (337 + 1G®A,
1290 + 1G®C, and 1292±2 A®G), and one missense mutation
(G11S) (Table I). Figure 1 depicts the results of our mutation
detection strategy in Family 3. In heterozygous patients, the wild-
type allele was distinguished from the mutant allele using a
combination of conformation sensitive gel electrophoresis (CSGE)
and automated sequencing on an ABI Prism 310 Genetic Analyzer
from Applied Biosystems (Perkin Elmer, Foster City, CA). All
mutations reported in this study were initially identi®ed by CSGE
analysis as mutation screening technique. Subsequent automated
sequencing of the PCR fragments showing altered mobility
revealed the underlying mutations. These mutations were absent
in 200 normal chromosomes studied for control purposes.
The molecular heterogeneity of VP is demonstrated by several
different mutations reported in the PPO gene to date, overviews
were previously given by Frank and Christiano (1998) and Whatley
et al (1999).
Interestingly, in the majority of the reported cases of VP,
mutations are unique in each individual family; however, recent
haplotyping analyses revealed three exceptions to this rule. Due to a
founder effect, R59W is present in approximately 96% of all South
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Table I. VP patients and their family membersa
Family Ethnic origin Mutation
VP 1±01 P American Q435X/±
02 S Q435X/±
03 S Q435X/±
VP 2 P American 1083delT/±
VP 3±01 P American, Indian, 1144delGT/±
02 S German 1144delGT/±
03 D 1144delGT/±
04 B/P 1144delGT/±
05 B ±/±
VP 4 P American 1091insA/±
VP 5±01 P American 333 + 1G®A/±
02 S ±/±
03 GS ±/±
VP 6 P English, Italian Q189X/±
VP 7±01 P Turkish 1291±2 A®G/±
02 D ±/±
03 F ±/±
VP 8±01 P American 1290 + 1G®C/±
02 S ±/±
03 S ±/±
04 S ±/±
VP 9±01 P American, German E191X/±
02 M E191X/±
03 D E191X/±
04 D ±/±
05 Si ±/±
06 B E191X/±
07 B E191X/±
VP 10±01 P American, Italian 915delTG/±
02 M ±/±
03 Si ±/±
VP 11±01 P American, Dutch Q189X/±
02 M ±/±
03 D ±/±
VP 12±01 P American 1144delGT/±
02 M ±/±
03 F ±/±
04 Si ±/±
05 B ±/±
VP 13±01 P American G11S/±
02 M ±/±
03 F G11S/±
aIndicated are the ethnic origin of each family and the presence/absence of a
mutation in the PPO gene. P, patient; M, mother; F, father; D, daughter; S, son;
Si, sister; B, brother; GS, grandson.
African patients with VP (Meissner et al, 1996; Groenewald et al,
1998). Recently, we showed that 1239delTACAC represents a
novel founder mutation in the Chilean population, whereas
R168H is the ®rst demonstrable hotspot mutation in VP (Frank
et al, 2000).
Our results re¯ect further exceptions to this rule: Two
mutations, Q189X and 1144delGT, respectively, were detected
in four apparently unrelated families (Table I). Interestingly, four
additional VP families carrying Q189X have been described by
other investigators. The same is true for the nonsense mutation
Q435X, recently also identi®ed in ®ve VP families from the U.K.
(Whatley et al, 1999). Future haplotyping analyses might elucidate
the question if these nonsense mutations are due to a founder effect
or represent hotspot mutations in the PPO gene.
Systematic molecular analyses and genetic counseling in families
with VP are very important, in particular because an acute
porphyric attack is a life-threatening condition, with a mortality
ranging from 2% to 10% (Lip et al, 1993). As clinical symptoms are
not overt in children before puberty (Kauppinen and Mustajoki,
1992), genetic analysis provides the only accurate method to
identify presymptomatic mutation carriers before they are exposed
to porphyrinogenic drugs or other factors that might precipitate an
acute porphyric attack (Crimlisk, 1997; Moore and Hift, 1997).
Particularly in families VP1, 3, and 9, in which several children
were identi®ed as mutation carriers, genetic diagnosis in the
presymptomatic state provides the possibility for early comprehen-
sive genetic counseling and should highten the attention of all
physicians treating those patients. Thus, the systematic identi®ca-
tion of mutation carriers within VP families is the ®rst and most
important step in the prevention of acute porphyric attacks.
The data presented here provide no evidence for the existence of
genotype-phenotype correlations. We did not observe a more
severe phenotypic expression of certain types of mutations, e.g.
those resulting in premature termination codon and thereby
abolishing PPO function. In contrast, we also found no correlation
between the phenotype and the underlying genetic lesion in
families where several family members carried the same mutation.
In family 9 (Fig 1), for example, the severity of clinical symptoms
within mutation carriers ranged from the complete absence of any
symptoms to the most severe combination of extreme photo-
sensitivity with recurrent neurologic attacks. These notions are
supported by recently published studies on 104 VP families from
Western Europe (Whatley et al, 1999).
DNA analysis is clearly the method of choice to con®rm a
putative diagnosis of VP, and consequently, to prevent acute attacks
in presymptomatic carriers of mutations. Further investigations are
underway to understand unusual mechanisms of inheritance in this
disease, and to develop gene replacement strategies for this disorder.
Figure 1. Mutation analysis in patient VP 3 and his family members. (A) Pedigree of the family with regard to the occurrence of variegate
porphyria (VP). All family members carrying the mutation 1144delGT are indicated by half-®lled squares and circles. (B) Hetero-
duplex analysis of family VP 3 and a control individual (C). Note the complex heteroduplex in all individuals carrying 1144delGT. (C) Automated
sequence analysis of the PCR fragment containing exon 11 of the PPO gene. Note the frameshift mutation (1144delGT) of the patient (lower panel)
compared with the wild-type sequence of an unrelated control (upper panel).
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Variations in the HCR (Pg8) Gene are Unlikely to be Causal
for Familial Psoriasis
To the Editor:
In a recent report Asumalahti et al identi®ed 12 coding variants
within gene HCR (Pg8) of the HLA class I region on chromosome
6 (Asumalahti et al, 2000). Two of these variants, C®T transitions
at nucleotide positions of 251 and 269, form an allele (the ``TT
allele'') that is strongly associated with psoriasis. Based on this
®nding, it was suggested that HCR may have a role in the
pathogenesis of psoriasis. We recently reported the ®ne mapping of
the PSORS1 susceptibility locus to a 60 kb segment of the HLA
class I region, between the HLA-C and corneodesmosin (CDSN)
genes (Nair et al, 2000). Using 34 closely spaced microsatellite
markers, we identi®ed 66 relatively homogeneous clusters of
haplotypes in 478 families and examined their association with
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